Sector: University & Research Institutions

Latest content

Patent suits decline in Dusseldorf and Mannheim, but Munich’s docket is on the rise

Germany is Europe’s biggest and most active litigation forum, but subtle differences in case law and proceedings mean that plaintiffs have important choices to make about where to file their suits

16 November 2021

Xperi highlights recent China deal as it seeks to "re-establish" its chip licensing business

Licence pact with Yangtze Memory heralds new applications for a technology that’s core to the company’s semiconductor holdings

15 November 2021

A multi-million-dollar patent damages win for J&J in China is good news for foreign rights holders

US company’s subsidiary secures major award against a local infringer at the Supreme People’s Court

12 November 2021

Moderna on IP collision course with US government

The company is at loggerheads with National Institutes of Health over inventorship of crucial covid vaccine technology

11 November 2021

IP rights are an important part of the push for more renewables

Saturday Opinion: IP protection is a significant driver of clean energy production, but it’s not the only key factor

06 November 2021

A $650 million deal is the latest in a growing number of CRISPR IP transactions

Last week’s licensing agreement between Mammoth and Vertex shows how deal-making in the space is gathering momentum

05 November 2021

European plausibility uncertainties could be cleared up by new Enlarged Board of Appeal referral

The EPO is seeking clarity on a crucial question facing patentees, but not everyone is sure that a recent referral is the best vehicle

04 November 2021

What patent numbers say about the quantum technology race

The Long Read: A gap between scientific publications and patent filings in quantum fields paints a worrying picture for European innovators, in particular, write Sebastien Ragot and Michel Kurek. However, there is still time for course correction

03 November 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales

01 November 2021

Get unlimited access to all IAM content